Potential efficacy of interleukin-1β inhibition in lung cancer

Lead researcher

Professor Brendan Jenkins

Main finding

Treatment with canakinumab, an antibody against IL-1beta, suppresses the development of lung cancer in individuals with athersclerosis.


Centre for Innate Immunity & Infectious Diseases

Research group

Cancer and Immune Signalling



Journal and article title

Most surprising

The study, CANTOS, was designed to assess the impact of anti-IL-1 therapy on atherosclerosis on a large cohort of individuals, however it was observed that there was a specific effect on reducing the incidence of lung cancer, yet not any other cancer.

Future implications

IL-1 therapy to now be investigated further in oncology for lung cancer

Disease/health impact

lung cancer

Professor Brendan Jenkins from the Cancer and Immune Signalling Research Group at Hudson Institute